CRISPR/Cas

Nuclear architecture investigation provides insights into the role of nuclear bodies in RNA processing.

CASGEVY^® is the first cell therapy based on the CRISPR/Cas9 technology, discoverers of which were awarded the Nobel Prize in Chemistry in 2020.

Discover how scientists produce CRISPR-edited cell populations.

There are many techniques that allow scientists to silence a gene, but whether the effect is transient or permanent depends on the type of approach.

By combining microscopy techniques with genome engineering, scientists revealed the complexities of the presynaptic actin cytoskeleton.

CRISPR-carrying lipid nanoparticles enabled researchers to correct a rare nonsense mutation in the lungs of a cystic fibrosis mouse model.

Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.

Researchers are using CRISPR for precise genetic manipulation of human-associated microbes as a promising avenue for improving human health.

Understanding how Cas9 binds off-target sequences can help researchers refine CRISPR-mediated genome editing.

CRISPR-Cas9 editing leads to widespread loss of the targeted chromosome in human T cells, but scientists recently discovered a way to prevent such loss.

CRISPR plasmids provide a robust solution for streamlining human cell transfection workflows.   

Drawing inspiration from nature, synthetic biology offers exciting opportunities to transform the future of medicine.

A study employing CRISPR/Cas9 to explore the evolutionary beginnings of some giant viruses finds evidence their large genomes arose from gene duplications.

Researchers optimize their transfection protocols with the ideal transfection reagent that has multiple applications, low cytotoxicity, and high transfection efficiency.

The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.

A study finds that CRISPR-Nickase, which changes just one allele of a given gene, improves gene editing efficiency compared with CRISPR-Cas9.

This month marks ten years since CRISPR-Cas9 was repurposed as a gene editing system, so we’re looking back at what has been accomplished in a decade of CRISPR editing.

Examining the major differences between Cas9 and Cas12

A first-of-its-kind gene therapy dramatically reduced misfolded protein levels in some clinical trial participants for up to six months and reduced levels in all participants for up to a year.